tetano
Editor, Senior Moderator
Muscle Nerve
. 2022 Dec 7.
doi: 10.1002/mus.27761. Online ahead of print.
Safety and immunogenicity of mRNA COVID-19 vaccine in inpatients with muscular dystrophy
Tomoko Saito[SUP] 1 [/SUP], Toshio Saito[SUP] 2 [/SUP], Hiroya Hashimoto[SUP] 3 [/SUP], Katsuhisa Ogata[SUP] 4 [/SUP], Michio Kobayashi[SUP] 5 [/SUP], Hiroto Takada[SUP] 6 [/SUP], Satoshi Kuru[SUP] 7 [/SUP], Takashi Kimura[SUP] 8 [/SUP], Akinori Nakamura[SUP] 9 [/SUP], Tsuyoshi Matsumura[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction/Aims Due to muscular weakness and cardiopulmonary dysfunction, patients with muscular dystrophy (MD) have an increased risk of serious complications from coronavirus disease 2019 (COVID-19). Although vaccination is recommended, COVID-19 vaccination safety and immunogenicity in these patients are unknown. We investigated reaction frequency, post-vaccine antibody titers after two mRNA COVID-19 vaccine doses, and clinical predictors of antibody response among patients with MD.
Methods: We recruited 171 inpatients with MD receiving two BNT162b2 mRNA COVID-19 vaccine doses from seven hospitals. Blood samples were obtained from 53 inpatients before the first dose and 28-30 days after the second dose, and antibody titers were measured.
Results: Overall, 104 (60.8%) and 115 (67.6%) patients experienced side effects after the first and second doses, respectively. These were generally mild and self-limited. Multiple logistic regression analysis showed that a bedridden state was associated with reduced side effects (OR: 0.29, 95% CI: 0.12-0.71). The antibody titers of all participants changed from negative to positive after two vaccine doses. The geometric mean titer (GMT) of the inpatients was 239 (95% CI: 159.3-358.7). Older age (RR=0.97, 95% CI: 0.95-0.99) and bedridden state (RR=0.27, 95% CI: 0.14-0.51) were associated with a lower antibody titer. Patients with myotonic dystrophy type 1 (DM1) had a lower GMT than patients with other MDs (RR=0.42, 95% CI: 0.21-0.85).
Discussion: COVID-19 vaccination is safe and immunogenic in inpatients with MD. Patients with DM1 appear to have a poorer COVID-19 antibody response than those with other MDs. This article is protected by copyright. All rights reserved.
Keywords: COVID-19 vaccination; ambulatory status; muscular dystrophy; myotonic dystrophy type 1; serum antibody titers.
. 2022 Dec 7.
doi: 10.1002/mus.27761. Online ahead of print.
Safety and immunogenicity of mRNA COVID-19 vaccine in inpatients with muscular dystrophy
Tomoko Saito[SUP] 1 [/SUP], Toshio Saito[SUP] 2 [/SUP], Hiroya Hashimoto[SUP] 3 [/SUP], Katsuhisa Ogata[SUP] 4 [/SUP], Michio Kobayashi[SUP] 5 [/SUP], Hiroto Takada[SUP] 6 [/SUP], Satoshi Kuru[SUP] 7 [/SUP], Takashi Kimura[SUP] 8 [/SUP], Akinori Nakamura[SUP] 9 [/SUP], Tsuyoshi Matsumura[SUP] 1 [/SUP]
Affiliations
- PMID: 36478587
- DOI: 10.1002/mus.27761
Abstract
Introduction/Aims Due to muscular weakness and cardiopulmonary dysfunction, patients with muscular dystrophy (MD) have an increased risk of serious complications from coronavirus disease 2019 (COVID-19). Although vaccination is recommended, COVID-19 vaccination safety and immunogenicity in these patients are unknown. We investigated reaction frequency, post-vaccine antibody titers after two mRNA COVID-19 vaccine doses, and clinical predictors of antibody response among patients with MD.
Methods: We recruited 171 inpatients with MD receiving two BNT162b2 mRNA COVID-19 vaccine doses from seven hospitals. Blood samples were obtained from 53 inpatients before the first dose and 28-30 days after the second dose, and antibody titers were measured.
Results: Overall, 104 (60.8%) and 115 (67.6%) patients experienced side effects after the first and second doses, respectively. These were generally mild and self-limited. Multiple logistic regression analysis showed that a bedridden state was associated with reduced side effects (OR: 0.29, 95% CI: 0.12-0.71). The antibody titers of all participants changed from negative to positive after two vaccine doses. The geometric mean titer (GMT) of the inpatients was 239 (95% CI: 159.3-358.7). Older age (RR=0.97, 95% CI: 0.95-0.99) and bedridden state (RR=0.27, 95% CI: 0.14-0.51) were associated with a lower antibody titer. Patients with myotonic dystrophy type 1 (DM1) had a lower GMT than patients with other MDs (RR=0.42, 95% CI: 0.21-0.85).
Discussion: COVID-19 vaccination is safe and immunogenic in inpatients with MD. Patients with DM1 appear to have a poorer COVID-19 antibody response than those with other MDs. This article is protected by copyright. All rights reserved.
Keywords: COVID-19 vaccination; ambulatory status; muscular dystrophy; myotonic dystrophy type 1; serum antibody titers.